Welcome to our dedicated page for Alterity Therapeutics news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics stock.
Alterity Therapeutics Limited develops treatments for neurodegenerative diseases, with a clinical program centered on Multiple System Atrophy and related Parkinsonian disorders. News about ATHE commonly covers ATH434, its lead MSA candidate, Phase 2 analyses, FDA interactions, chemistry, manufacturing and control updates, and presentations at neurology and imaging conferences.
Coverage also includes bioMUSE Natural History Study biomarker work, including quantitative susceptibility mapping MRI for iron dysregulation in MSA, Appendix 4C cash flow and corporate updates, board appointments, and discussions of the company’s drug discovery platform for patentable chemical compounds targeting neurological disease pathology.
Alterity Therapeutics (NASDAQ:ATHE) reported new data supporting advancement of ATH434 into Phase 3 for Multiple System Atrophy (MSA). Phase 2 analyses showed statistically significant slowing of functional decline at 50 mg BID (~48% reduction) and benefits on swallowing, alongside MRI and CSF biomarker evidence of target engagement.
An End-of-Phase 2 FDA meeting is planned for mid-2026 to confirm the Phase 3 path, supported by quantitative susceptibility mapping (QSM) and CSF NfL-based patient stratification.
Alterity Therapeutics (NASDAQ:ATHE) reported a peer-reviewed NeuroImage publication from its bioMUSE study showing quantitative susceptibility mapping (QSM) MRI detects disease-specific brain iron accumulation in Multiple System Atrophy, distinguishes MSA from Parkinson’s disease, and correlates with clinical severity. Alterity is advancing ATH434 toward a pivotal Phase 3 program, with FDA End-of-Phase 2 meeting targeted for mid-2026.
Alterity Therapeutics (NASDAQ: ATHE) announced multiple May 2026 medical conference presentations on its Multiple System Atrophy (MSA) development program.
Presentations include ISMRM (May 12, Cape Town), MDSANZ (May 15-17, Sydney) and MSA Symposium (May 18, London), featuring data and a clinical update on ATH434.
Alterity Therapeutics (NASDAQ: ATHE, ASX: ATH) released its Appendix 4C and a corporate update for Q3 FY26. Key items: FDA Type C feedback aligned on clinical pharmacology, non-clinical and CMC elements for a planned Phase 3 in MSA, with an End-of-Phase 2 meeting on track for mid-2026.
New Phase 2 analyses using the MuSyCA endpoint showed a treatment effect of −1.9 (75 mg) to −4.0 points (50 mg, p=0.034; relative effect 41%) at Week 52. Cash A$44.53M as of 31 March 2026; operating outflow A$4.73M for the quarter.
Alterity Therapeutics (NASDAQ: ATHE) received positive FDA feedback after a second Type C meeting on its planned ATH434 Phase 3 program in Multiple System Atrophy (MSA). The FDA provided written support for the program's chemistry, manufacturing, and control (CMC) elements, and manufacturing scale-up is progressing.
An End-of-Phase 2 meeting remains on track for mid-2026, moving the company closer to Phase 3 initiation while clinical pharmacology and non-clinical topics were addressed in an earlier Type C meeting.
Alterity Therapeutics (NASDAQ: ATHE) presented new analyses from the ATH434 Phase 2 MSA trial at AAN on April 22, 2026, showing ATH434 slowed functional decline versus placebo on a novel MuSyCA composite scale and on modified UMSARS Part I.
MuSyCA showed placebo worsening ~+9.7 points at Week 52; ATH434 treatment effects ranged from −1.9 (75 mg) to −4.0 points (50 mg, p=0.034). Modified UMSARS I effects were −3.1 (75 mg) and −4.7 points (50 mg, p=0.029). Data support ATH434's clinical profile ahead of Phase 3 regulator engagement.
Alterity Therapeutics (NASDAQ: ATHE) appointed Ann Cunningham as an independent Non-Executive Director effective 17 April 2026. The appointment adds >25 years of global pharmaceutical and biotech commercial experience as Alterity prepares to advance ATH434 into Phase 3 development for Multiple System Atrophy (MSA).
Ms Cunningham’s background includes senior commercial roles at Lilly and Teva, founder/CEO of i³ Strategy Partners, prior leadership on product launches including Cymbalta and Rexulti, and a board role at Vistagen Therapeutics.
Alterity Therapeutics (NASDAQ: ATHE) announced a Late-Breaker oral presentation at the American Academy of Neurology Annual Meeting on April 21, 2026, highlighting positive clinical signals for ATH434 in Multiple System Atrophy (MSA) using the MuSyCA composite scale.
The company reported clinically meaningful efficacy in a randomized Phase 2 trial, positive open-label data in advanced MSA, and said it is preparing to initiate a Phase 3 pivotal trial.
Alterity Therapeutics (NASDAQ: ATHE) will host a virtual KOL event on April 28, 2026 (US) and April 29, 2026 (Australia) to share new insights on ATH434 for Multiple System Atrophy (MSA). The session will review Phase 2 data and provide a high-level Phase 3 planning overview.
Alterity Therapeutics (NASDAQ: ATHE) received positive feedback from a Type C meeting with the FDA on March 30, 2026, supporting its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA).
The FDA provided written support for the company’s clinical pharmacology and non-clinical development elements. Alterity said it will seek agreement on CMC and the Phase 3 trial design, with an End-of-Phase 2 meeting on track for mid-year 2026.